Akanda Corp. Names Dr. Sunny Nayee as U.K. Medical Director to Support Partnership with Cellen Life Sciences

Expert in Chronic Pain Management Joins International Medical Cannabis Company

International medical cannabis company Akanda Corp. ("Akanda" or the “Company”) today announced that it has named Dr. Sunny Nayee as its new UK Medical Director. The appointment of Dr. Nayee, a pain treatment expert with direct experience in cannabis therapies, builds upon the company’s partnership with Cellen Life Sciences by combining one of the UK’s top prescribing doctors of medical cannabis with one of the UK’s first fully-digital pain clinics to greatly expand patient access. At Akanda, Dr. Nayee will be responsible for monitoring and improving the overall level of care provided to medical patients in the UK, as well as helping assess expansion into other international markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005890/en/

Dr Sunny Nayee newly appointed as UK medical director at Akanda Corp. (Photo: Business Wire)

Dr. Nayee joins Akanda from the Lyphe Group, a cannabis clinical telehealth and dispensing ecosystem, where he served as Medical Director. Dr. Nayee has been prescribing cannabis to his patients since 2019, and currently treats in excess of 1,000 patients. Under his leadership at Lyphe, The Medical Cannabis Clinics became the first ever cannabis clinic to receive a “good” rating from the Care Quality Commission.

“It is an honor to welcome Dr. Nayee to the Akanda team as we work to build the first seed-to-patient model, serving medical cannabis patients in the UK and Europe,” commented Tej Virk, Akanda’s CEO. “Dr. Nayee is a renowned pain treatment expert with direct experience in cannabis therapies. This makes him the ideal face of Akanda for patients. I’m looking forward to having Dr. Nayee by our side as we build a patient-oriented supply chain in the UK and eventually other international markets.”

“My focus has always been on accurately diagnosing patients then giving them access to the best treatment options available,” added Dr. Nayee. “I’m excited to join up with Akanda and Cellen to play a fundamental role in helping to democratize access to medical cannabis for patients in need.”

Dr. Nayee’s role comes at a pivotal time for the company as Akanda recently signed a Memorandum of Understanding with Cellen Life Sciences, a health tech company that provides treatment to chronic pain patients through its digital pain clinic, Leva Clinic. Sunny will be working closely with Cellen to enable Akanda to better address unmet healthcare needs of patients globally, starting with the UK. The MOU established a formal working relationship to optimize medical cannabis supply chain activities across Cellen and Akanda business interests, to increase supply and choice for patients in the UK.

Dr. Nayee has a distinguished and prize winning career. He trained at Cambridge University Medical School and is on staff at Imperial College Healthcare Trust, London’s Leading University Hospital. Dr. Nayee has been awarded the Industry Leading Canex “Superdoc” Award for being a “been a true advocate for medical cannabis and an adamant educator.” He also holds prizes from the NHS Strategic Health Authority’s innovation committee and Royal College of General Practitioners for work related to patient safety. He presents widely and most recently published research reviewing the safety and effectiveness of medical cannabis treatment for the treatment of chronic refractory pain, including presenting at the National Patient Safety Conference. He continues to work collaboratively with research teams at the University of Sydney Quest Research Group, Drug Science and BOD science. He plays an active role in multiple professional bodies including the British Pain Society, Spinal Interventional Society, World Institute of Pain and the European Pain Federation.

About Akanda Corp.

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. The company is building a seed-to-patient supply chain, connecting patients in the UK and Europe with diverse products including cannabis products cultivated at its competitively advantaged grow operation in the Kingdom of Lesotho and with other trusted third-party brands. Akanda’s initial portfolio includes Bophelo Bioscience & Wellness, a GACP qualified cultivation campus in the Kingdom of Lesotho in Southern Africa, and CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK.

Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". Forward-looking information may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005890/en/